ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: A randomized phase 2 study

Paolo Strati; Michelle A. Fanale; Yasuhiro Oki; Francesco Turturro; Luis E. Fayad; Nancy L. Bartlett; Douglas E. Gladstone; Yvette L. Kasamon; Carol S. Portlock; Wyndham H. Wilson; Andre Goy; Anas Younes; Hun Ju Lee

doi:10.3324/haematol.2018.199844

ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: A randomized phase 2 study

Paolo Strati, Michelle A. Fanale, Yasuhiro Oki, Francesco Turturro, Luis E. Fayad, Nancy L. Bartlett, Douglas E. Gladstone, Yvette L. Kasamon, Carol S. Portlock, Wyndham H. Wilson, Andre Goy, Anas Younes, Hun Ju Lee

Research output: Contribution to journal › Letter › peer-review

14 Scopus citations

Original language	English
Pages (from-to)	e65-e67
Journal	Haematologica
Volume	104
Issue number	2
DOIs	https://doi.org/10.3324/haematol.2018.199844
State	Published - Jan 31 2019

Access to Document

10.3324/haematol.2018.199844

Cite this

Strati, P., Fanale, M. A., Oki, Y., Turturro, F., Fayad, L. E., Bartlett, N. L., Gladstone, D. E., Kasamon, Y. L., Portlock, C. S., Wilson, W. H., Goy, A., Younes, A., & Lee, H. J. (2019). ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: A randomized phase 2 study. Haematologica, 104(2), e65-e67. https://doi.org/10.3324/haematol.2018.199844

@article{ffa4c743b0c247e9896f83ad53c91b00,

title = "ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: A randomized phase 2 study",

author = "Paolo Strati and Fanale, {Michelle A.} and Yasuhiro Oki and Francesco Turturro and Fayad, {Luis E.} and Bartlett, {Nancy L.} and Gladstone, {Douglas E.} and Kasamon, {Yvette L.} and Portlock, {Carol S.} and Wilson, {Wyndham H.} and Andre Goy and Anas Younes and Lee, {Hun Ju}",

year = "2019",

month = jan,

day = "31",

doi = "10.3324/haematol.2018.199844",

language = "English",

volume = "104",

pages = "e65--e67",

journal = "Haematologica",

issn = "0390-6078",

number = "2",

}

Strati, P, Fanale, MA, Oki, Y, Turturro, F, Fayad, LE, Bartlett, NL, Gladstone, DE, Kasamon, YL, Portlock, CS, Wilson, WH, Goy, A, Younes, A & Lee, HJ 2019, 'ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: A randomized phase 2 study', Haematologica, vol. 104, no. 2, pp. e65-e67. https://doi.org/10.3324/haematol.2018.199844

TY - JOUR

T1 - ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma

T2 - A randomized phase 2 study

AU - Strati, Paolo

AU - Fanale, Michelle A.

AU - Oki, Yasuhiro

AU - Turturro, Francesco

AU - Fayad, Luis E.

AU - Bartlett, Nancy L.

AU - Gladstone, Douglas E.

AU - Kasamon, Yvette L.

AU - Portlock, Carol S.

AU - Wilson, Wyndham H.

AU - Goy, Andre

AU - Younes, Anas

AU - Lee, Hun Ju

PY - 2019/1/31

Y1 - 2019/1/31

UR - http://www.scopus.com/inward/record.url?scp=85060939152&partnerID=8YFLogxK

U2 - 10.3324/haematol.2018.199844

DO - 10.3324/haematol.2018.199844

M3 - Letter

C2 - 30190343

AN - SCOPUS:85060939152

SN - 0390-6078

VL - 104

SP - e65-e67

JO - Haematologica

JF - Haematologica

IS - 2

ER -

ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: A randomized phase 2 study

Access to Document

Other files and links

Cite this